Presentation
13 March 2024 Photobiomodulation biphasic mechanisms in the treatment of renal fibrosis: evidence from in vitro and in vivo studies
Peter Bian, Ann Liebert, Helen Huang, Brian Bicknell, Carol Pollock
Author Affiliations +
Abstract
Renal disease is a severe and increasing problem with chronic kidney disease (CKD) associated with increasing incidence of obesity and metabolic disease. Current treatments for diabetic kidney disease are limited and generally ineffective, highlighting the need for innovative therapeutic strategies. Photobiomodulation is one such potential therapy. PBM is known to modulate cellular function, suppress inflammation, restore balance redox, and improve mitochondrial activity, all of which are hallmarks of CKD. Here we highlight photobiomodulation treatment for CKD in in vitro and in vivo models, with implications for photobiomodulation mechanisms. In vitro results showed that low-dose photobiomodulation resulted in over-expression of fibronectin and tumour necrosis factor and down-regulation of glutathione peroxidase while high-dose photobiomodulation did not. Similarly, in vivo results also showed that low but not high-dose PBM improved kidney function, decreased blood urea, albumin, albumin-creatinine ratio and other markers of CKD. There were significant microbiome changes associated with photobiomodulation treatment.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Peter Bian, Ann Liebert, Helen Huang, Brian Bicknell, and Carol Pollock "Photobiomodulation biphasic mechanisms in the treatment of renal fibrosis: evidence from in vitro and in vivo studies", Proc. SPIE PC12826, Mechanisms of Photobiomodulation Therapy XVIII, PC1282608 (13 March 2024); https://doi.org/10.1117/12.3009038
Advertisement
Advertisement
KEYWORDS
In vitro testing

In vivo imaging

Kidney

Diseases and disorders

Parkinson disease

Alzheimer's disease

Brain diseases

Back to Top